Order momentum - Co said strong order momentum from Q1 continued into Q2, supporting revenue growth
Portfolio diversification - Co attributed growth to strength and diversification of its product portfolio
Acquisition agreement - Co said definitive agreement to acquire BioLife Solutions is expected to strengthen cell therapy business and be accretive to revenue growth and margins
Outlook raised for FY26
Repligen raises FY26 organic revenue growth guidance to 10.5%-13.5%
Company now sees FY26 adjusted EPS of $2.03-$2.09
Repligen expects BioLife Solutions acquisition to be accretive to revenue growth and margin
Q2 results beat estimates
US bioprocessing technology firm's Q2 revenue rose 12%, beating analyst expectations
Q2 adjusted EPS increased to $0.54, beating analyst consensus
RGEN•
